Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Roche is a Swiss multinational pharmaceutical and diagnostics company operating two core divisions: Pharmaceuticals (oncology-focused blockbusters including Tecentriq, Ocrevus, Hemlibra) and Diagnostics (global leader in in-vitro diagnostics with ~30% market share). The company's competitive moat stems from its oncology franchise, personalized healthcare integration between drugs and companion diagnostics, and a late-stage pipeline targeting high-value therapeutic areas including neuroscience and ophthalmology.
Roche generates revenue through patent-protected specialty pharmaceuticals with premium pricing power in oncology and rare diseases, coupled with recurring revenue from diagnostics consumables and service contracts. The integrated model creates competitive advantage: companion diagnostics identify patients for targeted therapies (e.g., PD-L1 testing for Tecentriq), driving both drug and test adoption. Pharmaceutical margins exceed 75% gross, while diagnostics operates at 50-55% gross margins with razor-razorblade economics on installed instrument base. Pricing power stems from clinical differentiation, limited biosimilar competition in newer biologics, and essential diagnostic infrastructure in hospital networks.
Phase 3 clinical trial readouts for pipeline assets (particularly gantenerumab for Alzheimer's, ophthalmology programs, next-generation cancer immunotherapies)
Biosimilar erosion rates on legacy blockbusters (Avastin, Rituxan/MabThera) versus growth in newer franchises (Tecentriq, Ocrevus, Hemlibra)
Diagnostics division organic growth rates and COVID-19 testing revenue normalization (post-pandemic baseline establishment)
Regulatory approvals and label expansions in major markets (FDA, EMA, China NMPA) for existing products and pipeline candidates
Currency headwinds from CHF strength against USD and EUR, given ~85% of revenue generated outside Switzerland
Biosimilar competition accelerating on legacy biologics portfolio: Avastin, Herceptin, Rituxan facing 30-50% price erosion in Europe, with US biosimilar penetration increasing. Estimated $8-10B revenue at risk through 2028 requiring offset from newer products.
Healthcare pricing pressure intensifying globally: US Inflation Reduction Act Medicare negotiation provisions, European reference pricing compression, China Volume-Based Procurement expansion to biologics. Threatens mid-single-digit annual price erosion across portfolio.
Regulatory pathway uncertainty for personalized medicine: Companion diagnostics require parallel approval with therapeutics, extending development timelines and increasing clinical trial complexity. FDA/EMA evolving standards for biomarker-driven approvals create execution risk.
Oncology immunotherapy competition from Merck (Keytruda dominance in PD-1 market), Bristol Myers Squibb, and emerging ADC platforms from Daiichi Sankyo/AstraZeneca. Tecentriq market share pressure in first-line lung cancer.
Diagnostics market share erosion from Abbott, Siemens Healthineers, and Danaher in core laboratory automation. Point-of-care testing disruption from decentralized diagnostic platforms reducing hospital lab volumes.
Pipeline execution risk: Gantenerumab Alzheimer's program faced setbacks; failure to deliver Phase 3 successes in neuroscience, ophthalmology would leave $15B+ revenue gap from biosimilar losses without offset.
Currency translation exposure: ~50% of revenue in USD, ~25% in EUR, but reporting in CHF creates earnings volatility. 10% CHF strengthening reduces reported revenue by ~CHF 3-4B annually.
Pension and post-retirement obligations: Defined benefit plans with ~CHF 20B in obligations. Interest rate sensitivity and longevity assumptions create potential funding requirement volatility, though currently well-funded.
Contingent liabilities from litigation: Ongoing product liability cases, patent disputes, and antitrust investigations create tail risk. Historical settlements have been manageable relative to cash generation.
low - Pharmaceutical demand is non-discretionary and driven by disease prevalence rather than GDP growth. Diagnostics has modest cyclical exposure through elective procedure volumes in hospitals, but essential testing (oncology, infectious disease) remains stable. Emerging market exposure (~15-20% of sales) creates some sensitivity to local economic conditions affecting healthcare budgets and reimbursement, but developed market dominance (US ~50%, Europe ~25%) insulates from broader cycles.
Rising rates create modest headwind through higher discount rates applied to long-duration pipeline assets in DCF valuations, compressing valuation multiples. However, Roche's strong balance sheet (net cash position estimated at CHF 5-8B) eliminates financing cost concerns. Rate increases strengthen USD relative to CHF, providing translation tailwind to USD-denominated revenues. Pension obligations (~CHF 20B) benefit from higher discount rates, reducing liability valuations.
minimal - Roche operates with investment-grade credit ratings (AA-/Aa3) and maintains net cash or minimal net debt position. No meaningful exposure to credit market conditions for funding operations. Customer credit risk is low given payer mix of government programs, large insurers, and hospital systems with established payment cycles.
value and dividend - Roche attracts defensive healthcare investors seeking stable cash flows, 3%+ dividend yield, and downside protection during market volatility. The 55.7% net income growth in recent period (likely reflecting one-time items or COVID normalization) is atypical; normalized growth expectations are mid-single-digits. Strong ROE of 41.2% and consistent FCF generation appeal to quality-focused value managers. Limited appeal to pure growth investors given mature product portfolio and modest organic growth, though pipeline optionality provides asymmetric upside.
low to moderate - Beta typically 0.6-0.8 versus broader market given defensive healthcare characteristics and Swiss domicile. Stock exhibits lower volatility than US biotech peers but higher than diversified pharma due to binary clinical trial outcomes and currency swings. Recent 54.4% six-month return is exceptional and likely reflects pipeline optimism or sector rotation rather than sustainable momentum. Institutional ownership concentrated among long-only healthcare specialists and European equity funds.